Abata Therapeutics to Present at Upcoming Investor and Industry Events in June

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June:

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, May 31, 2023
Information
Tags: 
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Immunity (medical), Regulatory T cell, Biology, Therapy, Innovation, Patient, Autoimmunity, Inflammation, Pharmaceutical industry
Geotags: 
UNITED STATES, NORTH AMERICA, NEW YORK, MASSACHUSETTS, BOSTON, MA
Organisation: 
ABATA THERAPEUTICS
Summary
Key Points: 
  • Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June:
    World Medical Innovation Forum: Panel discussion titled “The Innovation Gap: Old Dog, New Tricks – Reprogramming the Immune System” on Wednesday, June 14, 2023, at 9:15 a.m.
  • ET in Boston, MA.


Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June:

  • Jefferies Global Healthcare Conference: Presentation on Wednesday, June 7, 2023, at 3:30 p.m. ET in New York, NY.
  • World Medical Innovation Forum: Panel discussion titled “The Innovation Gap: Old Dog, New Tricks – Reprogramming the Immune System” on Wednesday, June 14, 2023, at 9:15 a.m. ET in Boston, MA.

About Abata Therapeutics

Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. Abata’s lead program is in progressive multiple sclerosis (MS), and its second program is in type 1 diabetes - both indications are tissue-specific autoimmune diseases with substantial unmet needs, supporting a strong rationale for Abata’s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Watertown, Mass. Please visit abatatx.com or follow us on Twitter or LinkedIn for more information.

Copyright: 
Copyright Business Wire 2023